Literature DB >> 7872762

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

P M Furneri1, G Bisignano, G Cerniglia, G Nicoletti, M Cesana, G Tempera.   

Abstract

The in vitro activities of rufloxacin and its metabolite, MF 922, were compared with those of ofloxacin, ciprofloxacin, erythromycin, and minocycline against Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma fermentans, and Ureaplasma urealyticum. Rufloxacin, MF 922, and ciprofloxacin shared similar activities against all mycoplasmas tested. (MICs for 90% of isolates tested [MIC90s], 0.5 to 4 micrograms/ml. Ofloxacin had the lowest MIC90s for U. urealyticum, M. fermentans, and M. hominis (MIC90s, 0.25 to 1 micrograms/ml) and erythromycin had the lowest MIC90 for M. pneumoniae (MIC90, 0.004 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7872762      PMCID: PMC188257          DOI: 10.1128/AAC.38.11.2651

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin.

Authors:  R J Fallon; W M Brown
Journal:  J Antimicrob Chemother       Date:  1985-06       Impact factor: 5.790

2.  In vitro activity of amifloxacin against Chlamydia trachomatis and Ureaplasma urealyticum.

Authors:  S Freeman; J Wormuth; J Cornett
Journal:  Eur J Clin Microbiol       Date:  1985-10       Impact factor: 3.267

3.  Antimycoplasmal activity of ofloxacin (DL-8280).

Authors:  Y Osada; H Ogawa
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

4.  In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.

Authors:  L D Liebowitz; J Saunders; G Fehler; R C Ballard; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

Review 5.  Clinical antibiotic resistance of Ureaplasma urealyticum.

Authors:  D Taylor-Robinson; P M Furr
Journal:  Pediatr Infect Dis       Date:  1986 Nov-Dec

6.  Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.

Authors:  T C Gasser; S C Ebert; P H Graversen; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

7.  Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis.

Authors:  R Krausse; U Ullmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

8.  In vitro antibiotic susceptibility testing of different strains of Mycoplasma fermentans isolated from a variety of sources.

Authors:  M M Hayes; H H Foo; H Kotani; D J Wear; S C Lo
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

9.  Susceptibility of genital mycoplasmas to antimicrobial agents.

Authors:  P Braun; J O Klein; E H Kass
Journal:  Appl Microbiol       Date:  1970-01

10.  In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors:  K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.